Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IV Pancreatic Cancer AJCC v8: early-phase trial registry
18 of 32 indexed Stage IV Pancreatic Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #477 of 28,707 conditions by registered trial count.
32 US clinical trials · 18 currently recruiting · #477 of 28,707 conditions by registered trial count
Stage IV Pancreatic Cancer AJCC v8: 32 US clinical trials tracked, 18 recruiting.
Stage IV Pancreatic Cancer AJCC v8 is the subject of 32 registered US clinical trials on ClinicalTrials.gov, 18 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition stage-iv-pancreatic-cancer-ajcc-v8
OPEN 18 | RECR 56% | LATE 2 | EARLY 28 | RANK #477 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Alcohol Intoxication (56% recruiting · 16 trials)
Stage IV Pancreatic Cancer AJCC v8 lists 18 open slots (56% of 32 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IV Pancreatic Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IV Pancreatic Cancer AJCC v8 is recruiting above its size-band peers.
18 of 32 indexed trials (56.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IV Pancreatic Cancer AJCC v8 research.
National Cancer Institute (NCI) accounts for 7 of 32 trials (21.9%). 16 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IV Pancreatic Cancer AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 32 trials that report a genuine target (sentinel values excluded). 27 of those (84.4%) plan for fewer than 100 participants.
-
Stage IV Pancreatic Cancer AJCC v8 research is mostly interventional.
31 interventional and 1 observational studies make up this index (96.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
32 total, page 1 of 1
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
University of Rochester
NCT06073431
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NRG Oncology
NCT06958328
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
NCT06998940
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
NCT04005690
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Anne Noonan
NCT04115163
TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
University of California, Davis
NCT07189195
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
National Cancer Institute (NCI)
NCT05053971
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Mayo Clinic
NCT07226856
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
NCT05685602
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Sameek Roychowdhury
NCT06906562
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
Mayo Clinic
NCT04858009
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
NCT07214298
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
M.D. Anderson Cancer Center
NCT03608631
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
City of Hope Medical Center
NCT04887805
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
NCT06381154
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
City of Hope Medical Center
NCT04158635
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
City of Hope Medical Center
NCT06454383
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
NCT07089940
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
NCT05554367
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
ECOG-ACRIN Cancer Research Group
NCT04233866
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
Flemming Forsberg
NCT04821284
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT01585805
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
National Cancer Institute (NCI)
NCT04548752
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
National Cancer Institute (NCI)
NCT03816358
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
NCT04132505
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
NCT04514497
Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study
M.D. Anderson Cancer Center
NCT04837118
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
OHSU Knight Cancer Institute
NCT05034627
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
NCT06115499
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
NCT04493060
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
Mayo Clinic
NCT03033225
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
NCT04524702
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 14 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IV Pancreatic Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IV Pancreatic Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IV Pancreatic Cancer AJCC v8 page
32 registered trials, 18 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 18 Stage IV Pancreatic Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Stage IV Pancreatic Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IV Pancreatic Cancer AJCC v8 condition card totals 32 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.